SARS — beginning to understand a new virus

Nature Reviews Microbiology

Volumn 1, Issue 3, 2003, Pages 209-218

  Stadler, Konrad ^a   Masignani, Vega ^a   Eickmann, Markus ^b   Becker, Stephan ^b   Abrignani, Sergio ^a   Klenk, Hans Dieter ^b   Rappuoli, Rino ^a  

^a CHIRON VACCINES   (Italy)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN;

ANIMAL; CLASSIFICATION; GENETICS; GENOMICS; HUMAN; IMMUNOLOGY; METABOLISM; PHYLOGENY; PHYSIOLOGY; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIROLOGY; VIRUS GENOME;

ANIMALS; GENOME, VIRAL; GENOMICS; HUMANS; PHYLOGENY; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL PROTEINS;

EID: 1642509113     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro775     Document Type: Article

References (51)

1. Peiris, J. S. M. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-1325 (2003).
2. Donnelly, C. A. et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361, 1761-1766 (2003).
3. Hon, K. L. et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 361, 1701-1703 (2003).
4. Peiris, J. S. M. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767-1772 (2003).
5. WHO. Acute respiratory syndrome in China. [online], (cited 15 Oct 2003)
6. WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. [online], (cited 15 Oct 2003).
7. Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967-1976 (2003).
8. Ksiazek, T. G. et al. A Nnvel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med.348, 1953-1966 (2003).
9. Fouchier, R. A. et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423, 240 (2003).
10. Kuiken, T. et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362, 263-270 (2003).
11. Riley, S. et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science 300, 1961-1966 (2003).
12. Lipsitch, M. et al. Transmission dynamics and control of severe acute respiratory syndrome. Science 300, 1966-1970 (2003).
13. Guan, Y. et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302, 276-278 (2003).
14. Normile, D. & Enserink, M. SARS in China: tracking the roots of a killer. Science 301, 297-299 (2003).
15. WHO. Severe acute respiratory syndrome (SARS) in Singapore. [online], (cited 15 Oct 2003), (2003).
16. Enjuanes, L. et al. in Virus Taxonomy (eds Regenmortel, M. H. V. et all) 835-849 (Academic Press, New York, 2002).
17. Marra, M. A. et al. The genome sequence of the SARS- associated coronavirus. Science 300, 1399-1404 (2003).
18. Rota, P. A. et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394-1399 (2003).
19. Zeng, F. Y et al. The complete genome sequence of severe acute respiratory syndrome coronavirus strain HKU-39849 (HK-39). Exp. Biol. Med. 228, 866-873 (2003).
20. Thiel, V. et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 84, 2305-2315 (2003).
21. Thiel, V, Herold, J., Schelle, B. & Siddell, S. G. Viral replicase gene products suffice for coronavirus discontinuous transcription. J. Virol. 75, 6676-6681 (2001).
22. von Grotthuss, M., Wyrwicz, L. S. & Rychlewski, L. mRNA cap-1 methyltransferase in the SARS genome. Cell 113, 701-702 (2003).
23. Lai, M. M. & Cavanagh, D. The molecular biology of coronaviruses. Adv. Virus Res. 48, 1-100 (1997).
24. van der Most, R. G. & Spaan, W. J. M. in The Coronaviridae. (ed. Siddell, S. G.) 11-31 (Plenum Press, New York, 1995).
25. de Haan, C. A. M., Masters, P S., Shen, X., Weiss, S. & Rottier, P J. M. The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology 296, 177-189 (2002).
26. Sola, I. et al. Engineering the transmissible gastroenteritis virus genome as an expression vector inducing lactogenic immunity. J. Virol. 77, 4357-4369 (2003).
27. Sarma, J. D., Scheen, E., Seo, S. H., Koval, M. & Weiss, S. R. Enhanced green fluorescent protein expression may be used to monitor murine coronavirus spread in vitro and in the mouse central nervous system. J. Neurovirol. 8, 381-391 (2002).
28. Jonassen, C. M., Jonassen, T. O. & Grinde, B. A common RNA motif in the 3' end of the genomes of astroviruses, avian infectious bronchitis virus and an equine rhinovirus. J. Gen. Virol. 79, 715-718 (1998).
29. Lai, M. M. & Holmes, K. V. in Fields' Virology. (eds Knipe, M. D. & Howley, M. P) 1163-1185 (Lippincott Williams & Wilkins, Philadelphia, 2001).
30. Ruan, Y. J. et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 361, 1779-1785 (2003).
31. Ksiazek, T. G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953-1966 (2003).
32. Snijder, E. J. et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 331, 991-1004 (2003).
33. Anand, K. et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra a-helical domain. EMBO J. 21, 3213-3224 (2002).
34. Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R. & Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300, 1763-1767 (2003).
35. Krokhin, O. et al. Mass Spectrometric Characterization of proteins from the SARS virus: a preliminary report. Mol. Cell Proteomics. 2, 346-356 (2003).
36. Cavanagh, D. in The Coronaviridae. (ed. Siddell, S. G.) 73-113 (Plenum Press, New York, 1995).
37. Kuo, L., Godeke, G. J., Raamsman, M. J. B., Masters, P. S. & Rottier, P. J. M. Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J. Virol. 74, 1393-1406 (2000).
38. Haijema, B. J., Volders, H. & Rottier, P. J. M. Switching species tropism: an effective way to manipulate the feline coronavirus genome. J. Virol. 77, 4528-4538 (2003).
39. Yu, X. J. et al. Putative hAPN receptor binding sites in SARS- CoV spike protein. Acta Pharmacol. Sin. 24, 481-488 (2003).
40. Tresnan, D. B. & Holmes, K. V. Feline aminopeptidase N is a receptor for all group I coronaviruses. Adv. Exp. Med. Biol. 440, 69-75 (1998).
41. Holmes, K. V, Zelus, B. D., Schickli, J. H. & Weiss, S. R. Receptor specificity and receptor-induced conformational changes in mouse hepatitis virus spike glycoprotein. Adv. Exp. Med. Biol. 494, 173-181 (2001).
42. Bosch, B. J., van der Zee, R., de Haan, C. A. M. & Rottier, P. J. M. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77, 8801-8811 (2003).
43. Bos, E. C., Luytjes, W. & Spaan, W. J. The function of the spike protein of mouse hepatitis virus strain A59 can be studied on virus-like particles: cleavage is not required for infectivity. J. Virol. 71, 9427-9433 (1997).
44. Gombold, J. L., Hingley, S. T. & Weiss, S. R. Fusion-defective mutants of mouse hepatitis virus A59 contain a mutation in the spike protein cleavage signal. J. Virol. 67, 4504-4512 (1993).
45. Taguchi, F. Fusion formation by the uncleaved spike protein of murine coronavirus JHMV variant cl-2. J. Virol. 67, 1195-1202 (1993).
46. Hingley, S. T., Leparc-Goffart, I., Seo, S. H., Tsai, J. C. & Weiss, S. R. The virulence of mouse hepatitis virus strain A59 is not dependent on efficient spike protein cleavage and cell-to-cell fusion. J. Neurovirol. 8, 400-410 (2002).
47. Steuben R., Pfleiderera, M. & Siddell, S. Proteolytic cleavage of the murine coronavirus surface glycoprotein is not required for fusion activity. J. Gen. Virol. 74, 183-191 (1993).
48. Cinatl, J. et al. Treatment of SARS with human interferons. Lancet 362, 293-294 (2003).
49. Cinatl, J. et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361, 2045-2046 (2003).
50. Olsen, C. W. A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. Vet. Microbiol. 36, 1-37 (1993).
51. Saitou, N. & Nei, M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406-425 (1987).